Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells

Developmental expression of STATs, nuclear factor-κB and inflammatory genes in the jejunum of piglets during weaning

(2016) Hongbo Yi et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells

(2015) Abdullah Alsuliman et al.   Molecular Cancer

Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses

(2015) Wei-Bei Wang et al.   Stem Cell Reports

Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression

(2015) Roberto Bellucci et al.   OncoImmunology

Immune Escape Mechanisms as a Guide for Cancer Immunotherapy

(2014) G. L. Beatty et al.   CLINICAL CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival

(2013) Neil Romberg et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

(2012) X. Jiang et al.   CLINICAL CANCER RESEARCH

The Unholy Trinity: Inflammation, Cytokines, and STAT3 Shape The Cancer Microenvironment

(2011) Ning Li et al.   CANCER CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

STAT3 Negatively Regulates Type I IFN-Mediated Antiviral Response

(2011) W.-B. Wang et al.   JOURNAL OF IMMUNOLOGY

PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer

(2011) A. M. Gonzalez-Angulo et al.   MOLECULAR CANCER THERAPEUTICS

Immunity, Inflammation, and Cancer

(2010) Sergei I. Grivennikov et al.   CELL

PD-L1 expression on tolerogenic APCs is controlled by STAT-3

(2010) Sabine J. Wölfle et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling

(2009) L Lin et al.   ONCOGENE

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

(2008) T. Azuma et al.   BLOOD

The Protein Phosphatase Activity of PTEN Regulates Src Family Kinases and Controls Glioma Migration

(2008) N. Dey et al.   CANCER RESEARCH

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA